

# Material Information (3176 MEDIGEN?????)

SEQ_NO	1	Date of announcement	2024/08/06	Time of announcement	17:25:05
Subject	Complete Enrollment of PI-initiated Phase I Clinical Trial for OBP-301-Chemoradiation Combination Therapy in the U.S.				
Date of events	2024/08/06	To which item it meets	paragraph 53		

Statement	<p>1.Date of occurrence of the event:2024/08/06</p> <p>2.Company name:Medigen Biotechnology Corp.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: Medigen Biotechnology Corp. and the Japanese publicly traded company Oncolys BioPharma ("Oncolys", TSE stock code 4588), are jointly developing the oncolytic virus new drug OBP-301 (Telomelysin). Oncolys announced today (August 6, 2024) that enrollment of 15 patients for the investigator-initiated phase I clinical trial for OBP-301 in combination with chemoradiation in esophageal or gastro-esophageal cancer conducted in the United States ("The Study") has been completed. The Study aims to the patients with locally advanced esophageal or gastro-esophageal (GEJ) cancer who are not candidates for surgery. After demonstrating the safety of the combination in 6 patients in the dose finding cohort, an additional 9 patients were enrolled in the expansion cohort to further evaluate the safety and preliminary efficacy of OBP-301 with chemoradiation. The study is expected to provide important information about this novel combination treatment for patients with advanced esophageal or GEJ cancer who are ineligible for surgery.</p> <p>6.Countermeasures:none</p> <p>7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):</p> <p>(1)The development timeline for new drugs is long, the investment costs are high, and success is not guaranteed. These factors may pose risks to investors, who should make careful judgments and invest cautiously.</p> <p>(2)Our company shares the development costs of OBP-301 with Japan's Oncolys and will share in the future commercial benefits.</p> <p>(3)Link to the announcement from Japan's Oncolys: <a href="https://ssl4.eir-parts.net/doc/4588/tdnet/2484051/00.pdf">https://ssl4.eir-parts.net/doc/4588/tdnet/2484051/00.pdf</a></p>
-----------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------